GEN Exclusives

More »

GEN Poll

More »
Nov 22, 2011

Tool and Service Providers

Biotechnology tool and service companies will continue struggling with reduced demand from the academic segment of their customers and portions of the industry, if a check of third-quarter results is any indication. Details on how this could play out can be read here. Those that are performing well despite the downturn have a portfolio that spans instrumentation, consumables, and services. Last month, Frost & Sullivan issued a report concluding that the global contract research organization market resumed its growth trajectory last year and is expected to grow at a compound annual growth rate of 10.5% until 2017. For vendors dependent on installation of new systems as a primary source of revenue, things don’t look so rosy. Do you think consolidation will be the answer to such companies’ prayers?

Will firms focused on instrumentation survive the slowdown in demand through consolidation?

Yes
 
  70.4%
No
 
  14.8%
Undecided
 
  14.8%

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Tackling the Global Problem of Fake Medicines

Policy proposals to address the growing global problem of fake medicines include a global agreement, similar to the Framework Convention on Tobacco Control, and stricter national laws to prosecute those who knowingly sell counterfeit medicines. Do you think these steps will be successful?

More »